Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers

Hamon-Vilcot, Brigitte; Chaufour, S.; Deschamps, Chloé; Canal, M.; Zieleniuk, I.; Ahtoy, P; Chrétien, Pierre; Rosenzweig, P.; Nasr, Aml S.; Piette, F.

doi:10.1007/s002280050483

Cited by 35 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are in line with results from Hamon-Vilcot et al (1998). Cigarette consumption had no effect on the dose-corrected amisulpride plasma concentrations; interestingly, smokers received significantly higher doses of amisulpride than nonsmokers.…”

Section: Discussionsupporting

confidence: 89%

Plasma amisulpride levels in schizophrenia or schizoaffective disorder

Bergemann

Kopitz

Kress

et al. 2004

European Neuropsychopharmacology

View full text Add to dashboard Cite

The atypical antipsychotic drug amisulpride is a benzamide with specific antagonistic properties, which target dopamine D 2 and D 3 receptors, preferentially in the limbic system. Amisulpride is readily absorbed from the gastrointestinal tract, distributed to all body systems with little binding to plasma proteins. Elimination occurs mainly through the kidneys as unchanged drug. In contrast, hepatic metabolism is of minor significance and primarily yields two inactive metabolites. Very little is known about the plasma concentrations of amisulpride in patients at varying oral doses or about clinically relevant interactions with co-medication. The aim of the present investigation was to elucidate the factors, which affect amisulpride levels in schizophrenic patients. The plasma amisulpride levels of 85 patients with schizophrenia or schizoaffective disorder (mean age: 34.0 F 11.4 years; 40 women, 45 men) were assessed by high-performance liquid chromatography (HPLC) with fluorometric detection. The average daily dose of amisulpride was 772.3 mg (S.D. 346.7 mg) and the mean amisulpride plasma concentration was 424.4 ng/ml (S.D. 292.8 ng/ml). The interindividual variance of the amisulpride plasma concentration was high; furthermore, the plasma concentration increased linearly with the daily oral dose (r = 0.50, p < 0.001). Age and gender showed a significant effect on the dose-corrected amisulpride plasma concentrations -older patients and women had higher dose-corrected amisulpride plasma concentrations than younger patients and men. However, cigarette consumption had no effect on the amisulpride plasma concentrations. Regarding co-medication with lithium and/or clozapine, significantly higher amisulpride plasma concentrations were found as compared to monotherapy, whereas other co-medications such as benzodiazepines and various conventional antipsychotics had no effect on the amisulpride plasma concentrations. The results, the possible pathomechanisms and the clinical relevance are discussed. The findings need to be confirmed in larger patient samples and with a wider range of co-medications. D

show abstract

Section: Discussionsupporting

confidence: 89%

Plasma amisulpride levels in schizophrenia or schizoaffective disorder

Bergemann

Kopitz

Kress

et al. 2004

European Neuropsychopharmacology

View full text Add to dashboard Cite

show abstract

“…The doses were chosen on the basis of the current literature (pramipexole, Wright et al 1997;amisulpride, Legangneux et al 2000;Hamon-Vilcot et al 1998). Furthermore, single doses of pramipexole 0.5 mg were used in a recent study in our laboratory (Samuels et al 2006).…”

Section: Drugsmentioning

confidence: 99%

Comparison of pramipexole and amisulpride on alertness, autonomic and endocrine functions in healthy volunteers

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Furthermore, these patients may be more susceptible to drug interactions and metabolic changes (Katona, 2001). It is generally acknowledged that the atypical antipsychotic amisulpride has a satisfactory safety profile (among others good pharmacokinetic and cognitive-sparing profile) (Coulouvrat and Dondey-Nouvel, 1999;Ramaekers et al, 1999;Leucht, 2004), promotes social functioning (Saleem et al, 2002), and therefore seems to be a good candidate for treatment of the elderly patients (Hamon-Vilcot et al, 1998;Legangneux et al, 2000). This drug has been shown to be efficacious in dysthymic (Bellino et al, 1997) and psychotic (Möller et al, 2005) elderly patients and in the treatment of behavioural disturbances of patients with moderate to severe Alzheimer's disease (Mauri et al, 2006).…”

Section: Introductionmentioning

confidence: 99%